Next Article in Journal
Sodium Selenite Alleviates Breast Cancer-Related Lymphedema Independent of Antioxidant Defense System
Previous Article in Journal
The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management
Article Menu

Export Article

Open AccessArticle

Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases

1
Laboratory Medicine-Department of Pathology and Laboratory Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy
2
Bioinformatics and Biostatistics Unit-Department of Applied Research and Technological Development, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy
3
Epidemiology and Prevention Unit-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy
4
Immunohematology and Transfusion Medicine Service-Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy
5
Chair Cancer Experimental Therapeutics, Department of Oncology Faculty of Health Science, McMaster University, Hamilton, ON L8V 1C3, Canada
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Nutrients 2019, 11(5), 1020; https://doi.org/10.3390/nu11051020
Received: 5 April 2019 / Revised: 29 April 2019 / Accepted: 30 April 2019 / Published: 7 May 2019
  |  
PDF [491 KB, uploaded 7 May 2019]
  |     |  

Abstract

Metformin (MET) is currently being used in several trials for cancer prevention or treatment in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of total vitamin B12. In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET, whose participants were characterized by different components of metabolic syndrome, we tested the effect of MET on serum levels of B12, holo transcobalamin II (holo-TC-II), and methylmalonic acid (MMA). The study was conducted on 165 women receiving MET or placebo for three years. Results of the study indicate a significant overall reduction in both serum total B12 and holo-TC-II levels according with MET-treatment. In particular, in the MET group 26 of 81 patients and 10 of the 84 placebo-treated subjects had B12 below the normal threshold (<221 pmol/L) at the end of the study. Considering jointly all B12, Holo-TC-II, and MMA, 13 of the 165 subjects (10 MET and 3 placebo-treated) had at least two deficits in the biochemical parameters at the end of the study, without reporting clinical signs. Although our results do not affect whether women remain in the trial, B12 monitoring for MET-treated individuals should be implemented. View Full-Text
Keywords: metformin; vitamin B12; holotranscobalamin II; methylmalonic acid metformin; vitamin B12; holotranscobalamin II; methylmalonic acid
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Mastroianni, A.; Ciniselli, C.M.; Panella, R.; Macciotta, A.; Cavalleri, A.; Venturelli, E.; Taverna, F.; Mazzocchi, A.; Bruno, E.; Muti, P.; Berrino, F.; Verderio, P.; Morelli, D.; Pasanisi, P. Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases. Nutrients 2019, 11, 1020.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top